Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on October 24, 2025, reports the closing of a private placement of securities by Haoxi Health Technology Limited, a foreign private issuer. The filing covers the month of October 2025 and details the completion of a securities purchase agreement entered into on October 13, 2025.
Key Financial Metrics
- Gross Proceeds: $1.2 million raised from the sale of 5,217,391 Class A ordinary shares.
- Offering Price: $0.23 per share.
- Use of Proceeds: Working capital and general corporate purposes.
- Capital Structure Post-Closing: 7,503,028 Class A ordinary shares and 690,800 Class B ordinary shares issued and outstanding.
- Net Proceeds, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide clear values for these specific metrics beyond the gross proceeds figure.
Material Changes
The primary material change is the increase in outstanding share count following the closing of the private placement on October 22, 2025. The company issued new Class A shares to non-U.S. persons in reliance on Regulation S exemptions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the transaction mechanics. The transaction was executed under Regulation S of the Securities Act of 1933.
Investor Verification Checklist
- Verify the final net proceeds after deduction of customary expenses, as only gross proceeds ($1.2 million) are stated.
- Confirm the exact number of shares held by the "Purchasers" and any lock-up agreements associated with the new issuance.
- Review the company's current cash position to assess the immediate impact of the $1.2 million injection on working capital.
- Check for any subsequent filings regarding the utilization of proceeds for general corporate purposes.